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CommentaryThe Divine Comedy begins with the 
middle-aged poet Dante wandering 
alone through a dark forest, having 
lost his way on the “true path.” Driven 
deeper by frightening creatures block-
ing his escape route, he spies a human 
form that reveals itself to be the ghostly 
embodiment of the great Roman poet 
Virgil. Virgil offers to serve as Dante’s 
guide out of the dark forest to Heaven 
but warns him that to get there they 
must first pass through Hell and Pur-
gatory. Trusting his guide, Dante sets 
forth. What follows is a pilgrimage 
unlike any other recounted in Western 
literature, and Dante finds himself fun-
damentally changed forever.
Despite their ongoing financial suc-
cesses, the big pharmaceutical com-
panies have got to feel a bit like Dante 
at the beginning of a tough journey. 
Frightening creatures appear on an 
almost daily basis: A dwindling pipeline 
of potential new blockbuster drugs, 
endless news reports about excessive 
drug prices, competition from gener-
ics, stunning liability judgments, and 
demands for greater transparency in 
clinical trial data continue to push big 
pharma deeper into a dark forest of 
public approbation. The creatures are 
dangerous: within the last few weeks, 
Merck and Company announced plans 
to close five manufacturing plants, 
three research laboratories, and to lay 
off 11% of its work force (Berenson, 
2005). There is little empathy to be 
found in this world, as a recent Kaiser 
Family Foundation Health Poll Survey 
lists pharma’s public approval rating at 
an all time low, although still more favo-
rable than that of big oil and tobacco 
companies (Kaiser Family Foundation 
Health Poll Report Survey, 2005).
There is an abundance of litera-
ture examining what precipitated this 
dramatic fall into the darkness of dis-
trust. But the current negative press is 
nothing compared 
to the problems 
that big pharma will 
encounter unless it 
addresses its cur-
rent predicament. 
Pharma faces a trip 
through Hell and 
Purgatory before a 
better future is realized, but it must first 
find a trustworthy guide to get it there.
A Virgil for Pharma
There are many would-be Virgils vying 
for the attention and resources of big 
pharma, but only one resumé stands 
out. In the postgenomics era, the abil-
ity to unravel the mechanisms of dis-
ease in the context of the entire human 
organism through the marriage of basic 
and clinical research is within our grasp. 
Focused scientific research is the Virgil 
that offers the best hope for pharma to 
find its way into a new future.
Many may argue that pharma isn’t 
about scientific research per se but 
about the application of such research. 
Although that may have been true at a 
time when there was a limited possibil-
ity of fully understanding the molecular 
mechanisms of how drugs work, the 
current state of biomedical research 
renders this a false distinction. The 
recent lawsuits over the anti-inflamma-
tory drug Vioxx reveal the bankruptcy 
of our understanding of—and, in the 
public’s perception, pharma’s lack of 
interest in—mechanisms of disease 
in the context of the whole organism 
(Waxman, 2005; Frazier, 2005). The 
“bench” and the “clinic” are no longer 
sustainable as disparate areas of study, 
although many practitioners of one or 
the other have yet to fully appreciate 
that or figure out how to merge the two 
enterprises.
With the fully annotated human 
genome sequence available, an initial 
catalog of human genetic variation, 
amazing technological breakthroughs 
in whole genome studies, and grow-
ing insights from developmental biol-
ogy, we have before us the ability to 
look deeply into human biology and 
elucidate complete mechanisms of dis-
ease. An increase in our understanding 
of disease mechanisms should lead 
to new therapeutic interventions, but 
only if these efforts are led by scientific 
research that is open, collaborative, 
focused, and determined.
In the spirit of Dante’s quest, I think 
it is worth considering a few of the 
obstacles that big pharma faces on 
the journey ahead.
First Stop: The Inferno
Although “Hell” conjures up traditional 
punishment images of cloven-hooved 
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Hence, if the present world doth go astray,
In you the cause is, be it sought in you.
–Dante Alighieri, La Divina 
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demons and flames, the primary theo-
logical definition of Hell is “loss.” This 
deeper meaning goes to some of big 
pharma’s major fears about what may 
happen should it follow the scientific 
Virgil. Three closely related fears are 
immediately apparent.
The first and most obvious of these 
is financial. Pharma is convinced that 
it is in the business of human health, 
yet it really serves two masters. Phar-
ma’s shareholders demand—and have 
traditionally received— high returns on 
their investments. They rapidly pun-
ish those companies, or at least their 
corporate leaders, that do anything to 
threaten those returns. We have seen 
recently that the patience of new inves-
tors has a short time frame, whereas 
scientific research by its very nature 
cannot guarantee any specific dead-
line. As a result of this tension between 
expectations and reality, pharma are 
struggling to keep the “pipeline” of 
new drugs filled—particularly the late 
pipeline containing drugs in late-phase 
clinical trials. But there are not enough 
new drugs under development to fill 
every late pipeline to the satisfac-
tion of investors, and efforts to do so 
divert valuable resources and attention 
from the basic research that needs to 
be done to understand disease in its 
physiological environment and to dis-
cover potentially excellent new drugs 
with few side effects. A firm commit-
ment to rigorous and necessary scien-
tific research as the basis of future drug 
development may necessarily mean 
the loss of many current sharehold-
ers and the uncertainty regarding the 
arrival of more far-sighted investors.
A second major concern for pharma 
is that scientific research demands a 
high degree of transparency. Does it 
really cost $800 million or more (DiMasi 
et al., 2003) to discover and develop a 
new drug, and what exactly does that 
cost include? What are the data—all 
the data—that support a specific ave-
nue of inquiry? Pharma enjoys a fairly 
impenetrable curtain of protection 
about these and related questions, 
but to engage the scientific world will 
require that this curtain be torn away. 
Indications of the peril of doing so can 
be seen in the fulminant reaction to 
Marcia Angell’s analysis of drug devel-972 Cell 123, December 16, 2005 ©2005 Eopment cost and other issues in her 
book “The Truth about Drug Com-
panies” (Angell, 2004). In her book, 
Angell cites studies by Public Citizen 
(Public Citizen, 2001) and the Alliance 
on Tuberculosis Drug Development 
(Global Alliance for TB Drug Develop-
ment, 2001), concluding that the costs 
of drug development are not as high 
as pharma has suggested. Regardless 
of whether or not the analyses in the 
book are correct, the tone of the coun-
terattack indicates that the cost of 
drug development is not an area that 
could readily become transparent, at 
least any time soon (PHRMA, 2004).
A third fear goes to the very organi-
zational structure of most pharmaceu-
tical companies. There is a growing 
public perception that the amount of 
money spent on marketing a particular 
drug is out of proportion to the actual 
worth of the therapy being marketed, 
whether because of “just as good” 
but cheaper competitors or because 
the drug is targeted at “diseases” that 
are relatively benign. In an age where 
“blockbuster drugs” (a purely financial 
designation) reign, sales and market-
ing departments of pharma compa-
nies tend to be both large and to play a 
leading role in the directions a pharma 
company pursues. That will not change 
without a significant internal battle for 
the very soul of the company and will 
undoubtedly result in the loss of some 
traditional pharmaceutical jobs and a 
realignment of internal power, most of 
it coming to rest in the hands of the 
scientists who discover and develop 
the drugs.
Passing through the Purgatorio
Once pharma gets past the big cas-
ualties of the Inferno, there is still a 
need for a major realignment of what 
remains as pharma passes through 
the Purgatorio (the theological mean-
ing of Purgatory being “Purification”).
Understanding the molecular mech-
anisms of disease implies that “large 
markets” such as diabetes will be 
fractured into many smaller mecha-
nism-based patient populations. Just 
as there is no one genetic mechanism 
underlying type 2 diabetes, there is 
no one drug for all patients with this 
illness. Not that there is an infinite lsevier Inc.number of smaller markets—evolution 
simply won’t allow that much human 
variation—but there are more smaller 
markets than the single phenotype of 
many diseases would suggest. By its 
nature, this fragmentation of patient 
populations according to different 
mechanisms of disease will require 
a significant overhaul of regulatory 
approval procedures, “marketing,” 
patient and physician education, the 
role of academia, and even the funda-
mental pharma business model.
As mechanistic understanding cir-
cumscribes patient numbers, it will 
become increasingly impossible to do 
large-scale clinical trials, because in 
many cases there will not be enough 
patients to fully enroll a traditional trial. 
On the positive side, understanding 
disease mechanisms should enable 
the use of smaller, better-focused clini-
cal trials. But if pharma is unprepared 
to retool its drug development pro-
gram, drug regulatory agencies such 
as the U.S. Food and Drug Administra-
tion are even less well prepared. Much 
has been made of the partnership 
between industry and government in 
shortening approval times for drugs. 
It is time to bring that partnership to 
a new level that rethinks the approval 
process and redirects resources to 
make it happen.
The sad lack of scientific under-
standing by the general public cur-
rently assists pharma in its very suc-
cessful direct-to-consumer marketing 
through advertisements on televi-
sion and in magazines. This method 
of marketing certainly has benefits, 
but as drugs and drug combinations 
become more mechanism-based, 
direct-to-consumer marketing makes 
little sense given the generally poor 
scientific understanding of the general 
public. Thus, a huge educational effort 
has to happen. And not just for the 
would-be consumers, but for the phy-
sicians who prescribe these drugs and 
need to understand clearly how they 
work. Physicians will soon be faced 
with a palette of therapeutic options 
that will require a clear understanding 
of the multiple molecular contributions 
to the disease of the patient in front of 
them. The huge resources devoted 
to the current marketing corps of 
pharma companies could be retooled 
into a true educational operation, but 
only with significant changes. These 
include rethinking the entire rewards 
system (with its unforgiving empha-
sis on making the numbers) with the 
goal of providing a real understanding 
of how these drugs work, who should 
receive them, and how to determine 
this. Pharma already claims for itself a 
leading partnership in healthcare deliv-
ery. This kind of effort would make that 
claim more solid, both in the public 
perception of the industry and in fact.
Pharma is already hearing the foot-
steps of academia, which is rushing 
to fill the growing void in pharma’s 
pipeline of drugs in the early stages of 
discovery and even in development. 
Pharma may be yielding some of this 
ground but would do better to become 
an active partner with academia. This 
means not just licensing discover-
ies made at universities and research 
institutes but actively participating in 
the research under academic “rules.” 
More than just “splitting tasks” based 
on respective traditional strengths, this 
strategy would allow academia and 
pharma to inform each other through-
out the research and drug develop-
ment process. Working together, 
academia and pharma will build “trust, 
mutual scientific respect, and con-
comitant scientific goals” (Chin-Dust-
ing et al., 2005). That said, academia 
has picked up a few bad habits from its industrial partners, particularly in 
the areas of intellectual property and 
competitiveness that actually impede 
progress in biomedical research (Krim-
sky, 2003). It is time for academia to 
reclaim the scientific habits that are its 
foundation and that will ultimately ben-
efit its industrial partners on the path 
to the development of more effective 
drugs with fewer side effects.
“Blockbuster drugs” can still be 
developed in an increasingly frag-
mented market, but they can’t be the 
basis of a business model. Pharma 
companies can still be profitable—
perhaps not to the degree they have 
enjoyed so far—but still sufficiently so. 
However, given that pricing and profits 
necessarily will be transparent in this 
new world, pharma will have to trans-
form its business model in the glare of 
public attention if it is going to not only 
survive but also thrive.
At the Doorstep of a Paradiso
If pharma emerges from its tough jour-
ney, it will undoubtedly look very differ-
ent than it does now. It is impossible to 
say just how it will look, largely because 
this journey will not take place in isola-
tion. Societal issues such as health-
care costs, access to medicines, and 
even the ethics of prolonging life, as fil-
tered through elected bodies such as 
the U.S. Congress, will undoubtedly 
be as much a determinant of phar-
ma’s future as any changes it makes Cell 123, Decwithin. Yet the form that these exter-
nal influences take will be determined 
in large part by how proactive pharma 
is in undertaking tough adjustments to 
realize a better future.
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